Lee's Pharmaceutical Holdings Limited
LPCUF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | -0.00 | 0.00 |
| FCF Yield | 4.00% | -9,981.24% | 15,181.67% | -3.03% |
| EV / EBITDA | 3.36 | 0.18 | -0.11 | 2.48 |
| Quality | ||||
| ROIC | 3.95% | 1.19% | 3.75% | -0.02% |
| Gross Margin | 53.81% | 52.35% | 62.50% | 63.68% |
| Cash Conversion Ratio | 2.47 | 3.58 | 4.18 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.32% | -5.96% | 0.45% | 1.28% |
| Free Cash Flow Growth | 175.08% | -165.74% | 143.62% | -14.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.17 | -0.11 | -0.00 |
| Interest Coverage | 8.19 | 3.66 | 18.59 | -0.16 |
| Efficiency | ||||
| Inventory Turnover | 2.25 | 1.68 | 1.86 | 1.39 |
| Cash Conversion Cycle | 136.01 | 207.79 | 160.85 | 277.65 |